Disc Medicine (NASDAQ:IRON) Price Target Raised to $100.00 at WedbushMarket Beat·1 day ago, 12:42 PMIRON-0.85%
Disc Medicine management joins fireside chats at upcoming investor conferencesPUBT·1 day ago, 12:02 PMIRON-0.85%
Disc Medicine to Participate in Upcoming Investor ConferencesUnusual Whales·1 day ago, 12:02 PMIRON-0.85%
19:53 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire·2 days ago, 11:53 PMIRON-0.85%
Disc Medicine to present initial Phase 2 RESTORE-PV data for DISC-3405 in polycythemia vera at SOHO 2026PUBT·2 days ago, 10:00 PMIRON-0.85%
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting | IRON Stock NewsStockTitan·Aug 31 at 02:00 PMIRON-0.85%
Disc Medicine: Buy Rating Reiterated on Undervalued Hematology Pipeline, Upcoming Clinical Catalysts, and Unchanged $100 Price TargetTip Ranks·Aug 27 at 08:45 PMIRON-0.85%
Disc Medicine COO Jonathan Yen-Wen Yu disposes of 9,096 common shares worth $755,192.83PUBT·Aug 27 at 12:11 AMIRON-0.85%
19:24 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire·Aug 26 at 11:25 PMIRON-0.85%
13:32 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONprnewswire·Aug 22 at 05:33 PMIRON-0.85%
Will FDA Bitopertin Rejection and New Legal Probe Change Disc Medicine's (IRON) Narrative?Simplywall·Aug 20 at 07:45 AMIRON-0.85%
Disc Medicine CEO John D. Quisel disposes of USD 2.63 million in common sharesPUBT·Aug 18 at 10:57 PMIRON-0.85%
